Imatinib, a first line chemotherapeutic treatment for chronic myeloid leukemia, is a selective tyrosine kinase inhibitor of PDGF signaling, among other pathways including FLT3, Lck and MAPK cascades [180]. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.